SCHEMBL5660643

SCHEMBL5660643

CCOC(=O)C(C)(C)Oc1cccc(OCCCOc2ccc(OS(C)(=O)=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 6/20 0.52
▸ PPARG P37231 2/20 0.52
▸ FBP1 P09467 7/20 0.49
▸ TSHR P16473 2/20 0.47
▸ ABCB11 O95342 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ PMP22 Q01453 1/20 0.47
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ MAPK1 P28482 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ PPARD Q03181 1/20 0.42
▸ GRM2 Q14416 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ PLA2G4B P0C869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5660952 0.95 PPARA (0.54) PPARAPPARGFBP1TSHRABCB11
SCHEMBL5663196 0.91 PPARA (0.57) PPARAPPARGFBP1TSHRABCB11
SCHEMBL5661818 0.89 PPARA (0.65) PPARAPPARGFBP1TSHRABCB11
SCHEMBL5662983 0.88 PPARA (0.69) PPARAPPARGFBP1TSHRABCB11
SCHEMBL5660596 0.87 PPARG (0.53) PPARAPPARGFBP1TSHRABCB11
SCHEMBL5659151 0.86 FBP1 (0.48) PPARAPPARGFBP1TSHRABCB11
SCHEMBL5659323 0.86 PPARA (0.54) PPARAPPARGPPARD
SCHEMBL5660646 0.83 PPARA (0.48) PPARAPPARGFBP1TSHRABCB11
SCHEMBL5892173 0.83 PPARA (0.60) PPARAPPARGFBP1TSHRABCB11
SCHEMBL14526727 0.83 PPARG (0.52) PPARAPPARGFBP1TSHRABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 — — US claimed
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 — — US disclosed
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 — — US disclosed
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them GPR119, NR1H3, NR1H2 PPARA 251/4885PPARG 170/4885FBP1 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback